Related references
Note: Only part of the references are listed.Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Metabotropic Glutamate Receptors 5 Blockade Reverses Spatial Memory Deficits in a Mouse Model of Parkinson's Disease
Elvira De Leonibus et al.
NEUROPSYCHOPHARMACOLOGY (2009)
An expert opinion on safinamide in Parkinson's disease
Marco Onofrj et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Safinamide: Beyond MAO-B inhibition
C. Caccia et al.
PARKINSONISM & RELATED DISORDERS (2007)
Safinamide - From molecular targets to a new anti-Parkinson drug
C. Caccia et al.
NEUROLOGY (2006)
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity
A Marzo et al.
PHARMACOLOGICAL RESEARCH (2004)
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone
YWF Lam et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Share Paper
